Opiate Withdrawal Using Clonidine
- 25 January 1980
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 243 (4) , 343-346
- https://doi.org/10.1001/jama.1980.03300300021018
Abstract
Clonidine hydrochloride was administered to ten patients in an inpatient setting after abrupt discontinuation of chronic methadone hydrochloride administration. Clonidine produced a rapid and statistically significant decrease in opiate withdrawal signs and symptoms. Clonidine administration for 14 days enabled all patients to be successfully detoxified from chronic opiate administration. In all patients studied, clonidine was a safe and effective nonopiate treatment of opiate withdrawal that suppressed the affect, signs, and symptoms of opiate withdrawal. These data support the hypothesis that the α2-adrenergic agonist, clonidine, has substantial antiwithdrawal effect by replacing opiate-mediated inhibition with α2-mediated inhibition of brain noradrenergic activity. (JAMA243:343-346, 1980)Keywords
This publication has 8 references indexed in Scilit:
- Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawalAmerican Journal of Psychiatry, 1979
- Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidineNature, 1978
- OPIATE RECEPTORS: SOME ANATOMICAL AND PHYSIOLOGICAL ASPECTSAnnals of the New York Academy of Sciences, 1978
- Discontinuation of chronic clonidine treatment: Evidence for facilitated brain noradrenergic neurotransmissionNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1977
- Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the α-antagonist piperoxaneBrain Research, 1976
- Clonidine antinociceptive activity: Effects of drugs influencing central monoaminergic and cholinergic mechanisms in the ratNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1976
- Noradrenergic neurons: Morphine inhibition of spontaneous activityEuropean Journal of Pharmacology, 1974
- Interactions between 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, Catapresan®) and α-adrenergic blocking drugsEuropean Journal of Pharmacology, 1970